After a rare decline last month, AbbVie's Humira reclaimed its title as top advertised drug on TV with more than $40 million in spending.
The LAMA/LABA market is a crowded one, but GlaxoSmithKline has some new data in hand that it hopes can give it a leg up on a rival.
When Allergan CEO Brent Saunders said Wednesday that cost cuts were coming, he didn’t say where. But commercial chief Bill Meury did.
Now that Opdivo has posted 2017 growth, all eyes are on what the drug can pull off next year. And kidney cancer will factor in heavily.
WPP’s latest investment is all about patients. WPP Health & Wellness has partnered with The Mighty, an online community for patients and caregivers.
Astellas is debuting a new corporate branding campaign, asking, “What is the meaning of science?”
England's Cancer Drugs Fund will cover Roche's Tecentriq for bladder cancer after NICE rejected it for routine use.
Cutting-edge cell therapies from Novartis and Gilead aren't direct rivals for now, but with a new FDA filing, that could change—and soon.
Novartis' $3.9B deal for Advanced Accelerator Applications comes with a blockbuster-to-be, Lutathera, that could follow in Sandostatin's footsteps.
Astellas Oncology's C3 competition featured an AI-powered companion robot and a healthcare professionals’ app to facilitate diagnosis and treatment.